KORU Medical Systems, Inc.: Form 10-Q for the period ended Mar 31, 2021
Filed with the SEC on May 12, 2021 and accepted by EDGAR at May 12, 2021, 16:06 ET.
Risk factors
As filed, 5,534 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our operations and financial results are subject to various risks and uncertainties, including those described in “PART 1, ITEM 1A. RISK FACTORS” in our Annual Report on Form 10-K for the year ended December 31, 2020, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2020.
PART II – ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Prior to January 1, 2021, each non-employee director of the Company was eligible to receive $50,000 annually (effective January 1, 2019), plus $10,000 for chairing a Board committee (effective February 20, 2019), all to be paid quarterly half in cash and half in common stock. The Chairman of the Board was eligible to receive an additional $50,000 annually (effective October 1, 2019), all to be paid in common stock.
Effective January 1, 2021, each non-employee director of the Company (other than the Chairman of the Board) and Board advisor are eligible to receive of $75,000 annually, to be paid quarterly $12,500 in cash and $6,250 in common stock. The Chairman of the Board is eligible to receive $100,000 annually, to be paid quarterly $12,500 in cash and $12,500 in common stock. All payments were and are pro-rated for partial service. The Company issued an aggregate 10,124 shares of common stock to its non-employee directors during the three months ended March 31, 2021.
On May 20, 2020, the Company entered into a Settlement Agreement with EMED Technologies Corporation (“EMED”) to settle all claims in connection with all pending litigation matters between them. Pursuant to the Settlement Agreement, the Company issued to EMED (i) 95,238 restricted stock units, which vested on May 21, 2020 and 95,238 restricted stock units, which vested on January 1, 2021, and (ii) an option to purchase up to 400,000 shares of the Company’s common stock at an exercise price of $11.21 per share prior to February 1, 2021, which was not exercised.
During the three months ended March 31, 2021, 1,250,000 options to purchase shares of the Company’s common stock were issued to key employees under the Company’s 2015 Stock Option Plan, as amended, as follows:
- on January 15, 2021, options to purchase up to 150,000 shares to the Company’s interim Chief Executive Officer at an exercise price of $4.37 per share, of which all have vested;
- on March 15, 2021, options to purchase up to 1,000,000 shares to the Company’s incoming President and Chief Executive Officer at an exercise price of $3.875 per share, subject to vesting; and
- on March 1, 2021, options to purchase up to 100,000 shares to a key employee at an exercise price of $3.94 per share, subject to vesting.
On February 16, 2021, Donald Pettigrew, the Company’s former Chief Executive Officer, exercised options held by him for an aggregate 1,000,000 shares of common stock for an aggregate exercise price of $1,230,000.
All of the securities issued by the Company as described in this Item were issued in reliance on the exemption from registration under Section 4(2) under the Securities Act of 1933, as amended.
Issuer Purchases of Equity Securities
On November 16, 2020, the Company announced that its Board of Directors had authorized a stock repurchase program under which the Company may purchase up to $10.0 million of its outstanding common stock through December 31, 2021. As of March 31, 2021, the Company had purchased 683,271 shares for an aggregate $3,499,358 pursuant to this program.
The following table sets forth information regarding our repurchases of securities for each calendar month in the three months ended March 31, 2021:
| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs |
|---|---|---|---|---|
| January 1 to 31, 2021 | — | $0.00 | — | $6,500,642 |
| February 1 to 28, 2021 | — | 0.00 | — | $6,500,642 |
| March 1 to 31, 2021 | — | 0.00 | — | $6,500,642 |
| Total | — | $0.00 | — |
PART II – ITEM 6. EXHIBITS.
| 31.1 | Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002 |
| 31.2 | Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002 |
| 32.1 | Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002 |
| 32.2 | Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002 |
| 101* | Interactive Data Files of Financial Statements and Notes. |
* In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed”.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| REPRO MED SYSTEMS, INC. | |
| May 12, 2021 | /s/ Linda Tharby |
| Linda Tharby, President and Chief Executive Officer (Principal Executive Officer) | |
| May 12, 2021 | /s/ Karen Fisher |
| Karen Fisher, Chief Financial Officer and Treasurer (Principal Financial Officer) |
- 23 -
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-03-31 | $5.4m | us-gaap:Revenues |
| Cost of revenue | 3 months2021-01-01 to 2021-03-31 | $2.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-01-01 to 2021-03-31 | $3.2m | us-gaap:GrossProfit |
| Research and development | 3 months2021-01-01 to 2021-03-31 | $336.8k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2021-01-01 to 2021-03-31 | $5.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-01-01 to 2021-03-31 | −$2.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-01-01 to 2021-03-31 | −$942.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-01-01 to 2021-03-31 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-01-01 to 2021-03-31 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-01-01 to 2021-03-31 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-01-01 to 2021-03-31 | 43,960,936 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2021-01-01 to 2021-03-31 | −$2.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2021-01-01 to 2021-03-31 | $95.5k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2021-03-31 | $26.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-03-31 | $39.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-03-31 | $42.4m | us-gaap:Assets |
| Current liabilities | At period end2021-03-31 | $4.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-03-31 | $4.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-03-31 | $37.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001161697-21-000247. Last ingested by Listed: Nov 11, 2026, 02:24 ET. Listed shows no prices and gives no investment advice.